Zentalis Pharmaceuticals, Inc. (ZNTL) key performance indicators and operating metrics (5 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Cyclin E1-Positive Proportion of Platinum-Resistant Ovarian Cancer Patients | 50.00 percent | FY2026-Q1 |
| Denali Part 2b Target Enrollment | 70.00 | FY2025-Q3 |
| Target Enrollment in DENALI Part 2a per Dose Level | 30.00 | FY2025-Q2 |
| Number of Response-Evaluable Cyclin E1-Positive Platinum-Resistant Ovarian Cancer Patients in DENALI Part 1b | 43.00 | FY2025-Q1 |
| Objective Response Rate for DENALI Part 1b Response-Evaluable Cyclin E1-Positive Platinum-Resistant Ovarian Cancer | 34.90 percent | FY2025-Q1 |
Back to ZNTL overview · ZNTL earnings · ZNTL holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.